Villin1, a novel diagnostic marker for cervical adenocarcinoma

Nakamura, Etsuko; Iwakawa, Mayumi; Furuta, Reiko; Ohno, Tatsuya; Nakawatari, Miyako; Ishikawa, Ken-ichi; Imadome, Kaori; Michikawa, Yuichi; Tamaki, Tomoaki; Kato, Shingo; Kitagawa, Tomoyuki; Imai, Takashi

doi:10.4161/cbt.8.12.8477

Cited by 17 publications

(22 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is an anti-apoptotic epithelial protein that plays an essential role in regulating cellular morphology, survival and migration (26 were ECa and the remaining one case was diagnosed as small cell carcinoma of cervix, while no case of EMC was villin-positive (11). another study by Moll et al showed results similar to ours in that positive villin staining was found in only in 4/11 EMC (27).…”

Section: Discussionsupporting

confidence: 75%

“…Even if hysterectomy specimens were taken, it would be difficult to detect the original site of the carcinoma (10). Villin is an actin-binding protein which plays an important role in the maintenance of microvilli in epithelial cells and also has an essential role in the regulation of cell morphology and cell-specific epithelial anti-apoptotic mechanisms (11). Villin is also expressed in intestinal metaplasia and is associated with Barrett's esophagus and chronic atrophic gastritis, but it was not expressed in normal gastric and esophageal tissues (12).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Panel of villin, pro-ex-c, estrogen receptor and progesterone receptor expressions could help in differentiation between endocervical and endometrioid adenocarcinoma

Elfeky

Harb²,

Gertallah³

2017

TJPATH

View full text Add to dashboard Cite

Objective: Endocervical and endometrioid adenocarcinoma have marked overlapping features and the differentiation between them is important for their accurate management. Villin is an actin-binding protein which has an important role in the maintenance of microvilli in epithelial cells and epithelial cell-specific anti-apoptotic protein processes. Pro-Ex-C is a marker for higher-risk human papilloma virus (HPV) which targets the cell cycle proteins causing their overexpression. the aim of the study was to clarify the diagnostic and predictive role of villin, Pro-Ex-C, estrogen receptor (ER) and progesterone receptor (PR) expression in endocervical and endometrioid adenocarcinoma. Material and Method:We evaluated villin, Pro-Ex-C, ER and PR expressions in 15 cases of endocervical adenocarcinoma and 30 cases of endometrioid adenocarcinoma. We analyzed the diagnostic and predictive role of that panel in both carcinoma subtypes. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated. Results:Positive villin and Pro-Ex-C expressions were positively correlated with the presence and pattern of cervical stromal invasion (p<0.05). ER was positive in all cases of endometrioid adenocarcinoma. PR was detected in most cases of endometrioid adenocarcinoma. the differences of villin, Pro-Ex-C, ER and PR expression in endocervical and endometrioid adenocarcinoma was statistically significant (p<0.05). this methodology for distinguishing endocervical and endometrioid adenocarcinoma had a sensitivity of 100%, a specificity of 100% and a significant prognostic and predictive role.

show abstract

Section: Discussionsupporting

confidence: 75%

Section: Introductionmentioning

confidence: 99%

Panel of villin, pro-ex-c, estrogen receptor and progesterone receptor expressions could help in differentiation between endocervical and endometrioid adenocarcinoma

Elfeky

Harb²,

Gertallah³

2017

TJPATH

View full text Add to dashboard Cite

show abstract

“…We used some cervical cancer patients' tumor DNA containing HPV genome, which were detected in our previous experiments, as positive controls. The data indicated that the DNA samples used here showed good quality for PCR (24 Treatment. Patients were treated using a combination of external beam RT and high-dose rate brachytherapy.…”

Section: Patient Characteristics Between November 2001 Andmentioning

confidence: 79%

“…Genomic DNA was also isolated from biopsies frozen in RNAlater (Ambion; Thermo Fisher Scientific, Inc., Waltham, MA, USA) using the Genomic-tip 100/G kit (Qiagen GmbH). HPV genotypes were determined using the polymerase chain reaction (PCR) method (22) and the Linear Array HPV Genotyping test according to the manufacturer's instruction (Roche Molecular Diagnostics, Pleasanton, CA, USA) (23,24). Samples that contained more than about 70% of tumor cells were used in our study (22).…”

Section: Patient Characteristics Between November 2001 Andmentioning

confidence: 99%

Human papillomavirus genotype affects metastatic rate following radiotherapy in patients with uterine cervical cancer

et al. 2017

Self Cite

View full text Add to dashboard Cite

Abstract. Human papillomavirus (HPV) infection is well known as a major etiological risk factor associated with carcinogenesis in uterine cervical cancer. However, few reports have investigated the association between HPV genotype and outcome in patients with uterine cervical cancer following radiotherapy (RT). The aim of the present study was to investigate the association between the HPV genotype and clinical outcome following RT in Japanese patients with uterine cervical cancer. Between November 2001 and August 2006, 157 Japanese women with uterine cervical cancer were treated with RT or concurrent chemoradiotherapy with curative intent. Pretreatment, formalin-fixed, paraffin-embedded biopsies were obtained from 83 patients. HPV genotypes were determined using the polymerase chain reaction method. Patients were categorized, according to HPV L1 protein sequence homology, into the HPV α-9 (HPV 16,31,33, 52, and 58),39, 45, 59, and 68) or 'other' (HPV 51 and 56) groups. Associations between HPV genotype and clinical outcome following RT were evaluated. A total of 54 (65.1%) tumors were HPV α-9-positive, 13 (15.7%) were HPV α-7-positive, 2 (2.4%) were categorized under 'other' and 14 (16.9%) were HPV-negative. There were no significant differences in age, FIGO stage, regional lymph node metastases rate at diagnosis, or concurrent chemotherapy administration between the HPV α-9 and α-7 groups. The median follow-up period was 52 months (range, 2-156 months). The 5-year disease-free survival rates were 54.5 and 30.8% in the HPV α-9 and α-7 groups, respectively (P=0.034), and the 5-year distant metastasis rates were 38.0 and 69.2%, respectively (P=0.015). There were no significant differences in the 5-year local control or overall survival (OS) rates between the two groups. HPV genotype affected the 5-year distant metastatic rate, however not the 5-year local control or OS rate in patients with uterine cervical cancer following RT. IntroductionUterine cervical cancer (CC) is the second most common cancer among women, worldwide (1). The annual global incidence of CC in 2012 was 528,000 cases, and the annual global mortality rate was 266,000 deaths, with 85% of cases occurring in developing countries, where CC is a leading cause of cancer-related death in women (2). Oncogenic type human papillomavirus (HPV) infection is a major etiologic risk factor (3) associated with carcinogenesis (4). More than 100 HPV types have been identified, with a subset of these being classified as high risk. HPV 16 and HPV 18 are the most commonly detected genotypes occurring in 71% of invasive CCs (5). Current detection methods have uncovered a HPV prevalence of 95-100% in women with CC (6,7).The primary treatment strategy for uterine CC consists of surgery or radiotherapy (RT). Surgery is typically reserved for early-stage disease and small lesions including stage IA, IB1, and selected IIA1 diseases (8). Based on the results of randomized clinical trials, concurrent chemoradiotherapy (CCRT) has become the primary treatment for stage IB2...

show abstract

“…In this issue of Cancer Biology & Therapy, Nakamura and colleagues investigate a novel molecular biomarker for cervical AD through genomic analysis. 4 Nakamura et al focused on chromosomal regions where genetic alterations are frequently observed in cervical cancer. Chromosome 2q33.3-q36 was reported as a frequently deleted locus by array-CGH.…”

mentioning

confidence: 99%

A novel biomarker for cervical cancer

Takenaka¹

2009

Cancer Biology & Therapy

View full text Add to dashboard Cite

Villin1, a novel diagnostic marker for cervical adenocarcinoma

Cited by 17 publications

References 37 publications

Panel of villin, pro-ex-c, estrogen receptor and progesterone receptor expressions could help in differentiation between endocervical and endometrioid adenocarcinoma

Panel of villin, pro-ex-c, estrogen receptor and progesterone receptor expressions could help in differentiation between endocervical and endometrioid adenocarcinoma

Human papillomavirus genotype affects metastatic rate following radiotherapy in patients with uterine cervical cancer

A novel biomarker for cervical cancer

Contact Info

Product

Resources

About